What is the significance of an abnormal lipid profile in the development of myocardial infarction?

More Indunil Karunarathna's questions See All

Detection and Identification of Amanitins in the Wood-Rotting Fungi Galerina fasciculata andGalerina helvoliceps

Dear all, Can anyone help me to contact the corresponding author of the paper " Muraoka, S., Fukamachi, N., Mizumoto, K., & Shinozawa, T. (1999). Detection and Identification of Amanitins in...

01 January 1970 6,517 3 View

Edible mushrooms and their cultivation

Hi All, Does anyone have the PDF of following book? Chang, S. T.; Miles, P. G. (1989). Edible mushrooms and their cultivation. Edible Mushrooms and Their Cultivation, 345. Thanks

01 January 1970 7,851 1 View

Is there any test to determine the cardiovascular risk of patients with obesity? from the perspective of obesity?

We found tests to determine cardiovascular risk taking into account lipid profile, blood pressure, age, history of diabetes, other laboratories. But when weight is involved, there is a paradox. I...

02 March 2021 6,036 1 View

What is the state of the drug inside solid lipid nanoparticles (SLNs)?

I am a little confuse with the mechanism of solid lipid nanoparticles (SLNs). The main point of encapsulating drugs into SLNs is because some drugs have low solubility in water. Therefore, SLNs...

01 March 2021 3,703 3 View

Which database would give me this list of chemical components?

Dear colleagues: I would like to know if anyone knows of a database that gives me the parameters pH, K, K, Mg, P, C, N, Zn, Cu, Ni and Cd of common foods. I find a lot of information of proteins,...

26 February 2021 5,525 3 View

How to obtain free lipids starting from concentration over the CMC?

I need to work with free lipids at increasing concentration (50%, 60% of the CMC ect.). I'm now working with POPC and POPG. To reach these concentrations I have to start from concentration over...

17 February 2021 1,676 3 View

Solid Phase Extraction of drug product containing nanoparticles ?

Hi Everyone, I am trying to develop an SPE method for the vaccine which contains Matrix-M (saponin Quillaja Saponaria ) which is in nano-particle form and size is around 40nm. These nanoparticles...

16 February 2021 1,389 2 View

Which kind of GPC solvent can be used to dissolve both lipid and salt?

I want to find a GPC available solvent to dissolve both lipid (DPPC, 2 mM) and salt (NaCl, 100 mM).

14 January 2021 3,805 2 View

How to remove ORO (Oil red O) background precipitates?

Hi ORO experts, I'm struggling with ORO background precipitates in arterial tissues. The protocol I use works very well on human atherosclerotic plaques which are full of lipids and I don't...

13 January 2021 7,110 1 View

Why the lipid accumulation levels in my 3T3L1 does not match with my adipogenic and lipogenic gene expression levels?

I am using the 3T3-L1 cell line to discover the adipogenic effects of a natural compound and its derivatives. I conducted a lipid accumulation assay using fluorescent Nile Red dye (Adipored) for...

10 January 2021 4,360 1 View

What is the best protocol to extract bacterial genomic DNA from cheese?

Hello everyone, Actually I am trying to extract bacterial genomic DNA from cheese. I am using isolate II genomic DNA kit. Sometimes it gives good results but sometimes I don't get anything. This...

25 December 2020 2,452 1 View

Is it possible to calculate the sample size of a clinical trial with the Cohen formula when there is no similar article?

We are trying to design a clinical trial on type 2 diabetes patients. The main data that we want to assess include FBS, 2hpp, HbA1c, insulin, and HOMA-IR. Also, we will assess the lipid profile...

21 December 2020 2,454 3 View

William Feeman

Finding of an abnormal lipid profile in a patient with an AMI means that someone did not care enough to make an attempt to treat the dyslipidemia and (hopefully) prevent the AMI. That could be due to physician or patient factors, and I have seen both. Also, one must begin to treat early enough in the course of the atherothrombotic d9ise4ase (ATD) process. One can not begin treatment of dyslipidemia today and prevent an ATD event that is going to happen tomorrow. early detection and treatment is the answer and the USPTFS is just plain wrong about early (primordial) lipid testing. One needs to know where one started from to know where one is going.